Stock PHM PHARMA MAR, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pharma Mar, S.A.

Equities

PHM

ES0169501022

Real-time Estimate Tradegate
Other stock markets
 07:37:38 2024-04-30 am EDT 		5-day change 1st Jan Change
30.16 EUR +1.14% Intraday chart for Pharma Mar, S.A. +10.14% -26.00%
Apr. 23 Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 29 Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers
AQ
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication
MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong
MT
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China
AQ
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao
MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru
MT
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone
AQ
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal
MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023
AQ
PharmaMar increased investment in R&D in oncology by 23% in 2022
AQ
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa
AQ
PharmaMar will present new data on lurbinectedin at the IASLC 2023 World Lung Cancer Congress
AQ
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.
CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHM Stock
  4. News Pharma Mar, S.A.